Neuropsychopharmacology - Table of Contents alert Volume 37 Issue 1

TABLE OF CONTENTS Volume 37, Issue 1 (January 2012) In this issue Editorial Reviews Commentaries Hot Topics Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Neuropsychopharmacology Reviews Highlighting Neurotherapeutics in 2012 Published each January as a special issue of Neuropsychopharmacology, the 2012 edition highlights Neurotherapeutics, with a thorough look at hot topics in this area and in-depth review articles. Visit www.neuropsychopharmacology.org and gain access to these articles before they are published in print.   Editorial Top Neurotherapeutics Gwenn S Smith, Xiaohua Li and P Jeffrey Conn Neuropsychopharmacology 2011 37: 1-3; 10.1038/npp.2011.233 Full Text Reviews Top From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment Bita Moghaddam and Daniel Javitt Neuropsychopharmacology 2011 37: 4-15; advance online publication, September 28, 2011; 10.1038/npp.2011.181 Abstract | Full Text Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia Carrie K Jones, Nellie Byun and Michael Bubser Neuropsychopharmacology 2011 37: 16-42; advance online publication, September 28, 2011; 10.1038/npp.2011.199 Abstract | Full Text Cognitive Training for Impaired Neural Systems in Neuropsychiatric Illness Sophia Vinogradov, Melissa Fisher and Etienne de Villers-Sidani Neuropsychopharmacology 2011 37: 43-76; advance online publication, November 2, 2011; 10.1038/npp.2011.251 Abstract | Full Text Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development Xiaohua Li, Mark A Frye and Richard C Shelton Neuropsychopharmacology 2011 37: 77-101; advance online publication, September 7, 2011; 10.1038/npp.2011.198 Abstract | Full Text Somatic Treatments for Mood Disorders Moacyr A Rosa and Sarah H Lisanby Neuropsychopharmacology 2011 37: 102-116; advance online publication, October 5, 2011; 10.1038/npp.2011.225 Abstract | Full Text Cognitive Mechanisms of Treatment in Depression Jonathan P Roiser, Rebecca Elliott and Barbara J Sahakian Neuropsychopharmacology 2011 37: 117-136; advance online publication, October 5, 2011; 10.1038/npp.2011.183 Abstract | Full Text Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior Ebrahim Haroon, Charles L Raison and Andrew H Miller Neuropsychopharmacology 2011 37: 137-162; advance online publication, September 14, 2011; 10.1038/npp.2011.205 Abstract | Full Text Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation Giovanni Addolorato, Lorenzo Leggio, F Woodward Hopf, Marco Diana and Antonello Bonci Neuropsychopharmacology 2011 37: 163-177; advance online publication, October 26, 2011; 10.1038/npp.2011.216 Abstract | Full Text Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond Christina Gross, Elizabeth M Berry-Kravis and Gary J Bassell Neuropsychopharmacology 2011 37: 178-195; advance online publication, July 27, 2011; 10.1038/npp.2011.137 Abstract | Full Text Networking in Autism: Leveraging Genetic, Biomarker and Model System Findings in the Search for New Treatments Jeremy Veenstra-VanderWeele and Randy D Blakely Neuropsychopharmacology 2011 37: 196-212; advance online publication, September 21, 2011; 10.1038/npp.2011.185 Abstract | Full Text Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa Yoland Smith, Thomas Wichmann, Stewart A Factor and Mahlon R DeLong Neuropsychopharmacology 2011 37: 213-246; advance online publication, September 28, 2011; 10.1038/npp.2011.212 Abstract | Full Text Epigenetic Treatments for Cognitive Impairments Jeremy J Day and J David Sweatt Neuropsychopharmacology 2011 37: 247-260; advance online publication, May 18, 2011; 10.1038/npp.2011.85 Abstract | Full Text Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development Alena V Savonenko, Tatiana Melnikova, Andrew Hiatt, Tong Li, Paul F Worley, Juan C Troncoso, Phil C Wong and Don L Price Neuropsychopharmacology 2011 37: 261-277; advance online publication, September 21, 2011; 10.1038/npp.2011.211 Abstract | Full Text Commentaries Top New Era for Novel CNS Drug Development William Z Potter Neuropsychopharmacology 2011 37: 278-280; 10.1038/npp.2011.186 Full Text Translating Discoveries into Medicine: Psychiatric Drug Development in 2011 Linda S Brady and Thomas R Insel Neuropsychopharmacology 2011 37: 281-283; 10.1038/npp.2011.106 Full Text NIA Commentary: Translational Issues in Alzheimer’s Disease Drug Development Neil S Buckholtz, Laurie M Ryan, Suzana Petanceska and Lorenzo M Refolo Neuropsychopharmacology 2011 37: 284-286; 10.1038/npp.2011.116 Full Text Neuroscience Networking: Linking Discovery to Drugs Jill Heemskerk, Rebecca Farkas and Petra Kaufmann Neuropsychopharmacology 2011 37: 287-288; 10.1038/npp.2011.177 Abstract | Full Text New Medications for Substance Use Disorders: Challenges and Opportunities Nora D Volkow and Phil Skolnick Neuropsychopharmacology 2011 37: 290-292; 10.1038/npp.2011.84 Abstract | Full Text The Role of Complementary, Alternative, and Integrative Medicine in Personalized Health Care Emmeline Edwards Neuropsychopharmacology 2011 37: 293-295; 10.1038/npp.2011.92 Full Text Hot Topics Top Grateful DREADDs: Engineered Receptors Reveal How Neural Circuits Regulate Behavior Susan M Ferguson and John F Neumaier Neuropsychopharmacology 2011 37: 296-297; 10.1038/npp.2011.179 Full Text Dopamine D3 Receptor Function and Cocaine Exposure Brandi L Blaylock and Michael A Nader Neuropsychopharmacology 2011 37: 297-298; 10.1038/npp.2011.170 Full Text Chronic N-acetylcysteine after cocaine self-administration produces enduring reductions in drug-seeking Carmela M Reichel and Ronald E See Neuropsychopharmacology 2011 37: 298; 10.1038/npp.2011.164 Full Text Methamphetamine-Induced Oxidation of Proteins and Alterations in Protein Processing Bryan K Yamamoto and Fu-Chen Yang Neuropsychopharmacology 2011 37: 298-299; 10.1038/npp.2011.173 Full Text Placental Source for 5-HT that Tunes Fetal Brain Development Alexandre Bonnin and Pat Levitt Neuropsychopharmacology 2011 37: 299-300; 10.1038/npp.2011.194 Full Text Mainstreaming Mice Brooke A Babineau, Mu Yang and Jacqueline N Crawley Neuropsychopharmacology 2011 37: 300-301; 10.1038/npp.2011.168 Full Text Phospholipase D as a Therapeutic Target in Brain Disorders Craig W Lindsley and H Alex Brown Neuropsychopharmacology 2011 37: 301-302; 10.1038/npp.2011.178 Full Text Transferrin Antibodies Into the Brain Mark S Dennis and Ryan J Watts Neuropsychopharmacology 2011 37: 302-303; 10.1038/npp.2011.196 Full Text Endogenous Opioids as Physiological Antidepressants: Complementary Role of Delta Receptors and Dopamine Emily M Jutkiewicz and Bernard P Roques Neuropsychopharmacology 2011 37: 303-304; 10.1038/npp.2011.244 Full Text Oxytocin as a Potential Therapeutic Target for Schizophrenia and Other Neuropsychiatric Conditions David Feifel Neuropsychopharmacology 2011 37: 304-305; 10.1038/npp.2011.184 Full Text Dysregulation of mTOR Signaling in Neuropsychiatric Disorders: Therapeutic Implications Kirsty Sawicka and R Suzanne Zukin Neuropsychopharmacology 2011 37: 305-306; 10.1038/npp.2011.210 Full Text Habenular Signaling in Nicotine Reinforcement Christie D Fowler and Paul J Kenny Neuropsychopharmacology 2011 37: 306-307; 10.1038/npp.2011.197 Full Text Circuits, Cells, and Synapses: Toward a New Target for Deep Brain Stimulation in Depression Fritz A Henn Neuropsychopharmacology 2011 37: 307-308; 10.1038/npp.2011.193 Full Text Update on Corticotropin-Releasing Factor Pharmacotherapy for Psychiatric Disorders: A Revisionist View George F Koob and Eric P Zorrilla Neuropsychopharmacology 2011 37: 308-309; 10.1038/npp.2011.213 Full Text Update on Omega-3 Polyunsaturated Fatty Acids in Early-Stage Psychotic Disorders G Paul Amminger and Patrick D McGorry Neuropsychopharmacology 2011 37: 309-310; 10.1038/npp.2011.187 Full Text Beyond Antipsychotics: Pharmacologically-Augmented Cognitive Therapies (PACTs) for Schizophrenia Neal R Swerdlow Neuropsychopharmacology 2011 37: 310-311; 10.1038/npp.2011.195 Full Text From Father to Offspring: Paternal Transmission of Depressive-Like Behaviors David M Dietz and Eric J Nestler Neuropsychopharmacology 2011 37: 311-312; 10.1038/npp.2011.167 Full Text Advertisement Ensure your access to Neuropsychopharmacology If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Library recommendation through our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now.   Please note that you need to be a subscriber or site-license holder to enjoy full-text access to Neuropsychopharmacology. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.